Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Fujimaki, Katsumichi [1 ]
Miyashita, Kazuho [1 ]
Kawasaki, Rika [1 ]
Tomita, Naoto [2 ]
Ishigatsubo, Yoshiaki [2 ]
机构：
[1] Fujisawa City Hosp, Fujisawa, Kanagawa, Japan
[2] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
    Lee, Byung-Hyun
    Kang, Ka-Won
    Jeon, Min Ji
    Yu, Eun Sang
    Kim, Dae Sik
    Choi, Hojoon
    Lee, Se Ryeon
    Sung, Hwa Jung
    Kim, Byung Soo
    Choi, Chul Won
    Park, Yong
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [32] TREATMENT OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES RECEIVING AZACITIDINE WHO ARE ENROLLED IN AVIDA, A LONGITUDINAL PATIENT REGISTRY
    Grinblatt, L.
    Narang, X.
    Malone, M.
    Sweet, A.
    Dunne, S.
    Sullivan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 531 - 531
  • [33] Phase Ib study of eltrombopag and azacitidine in patients with high-risk myelodysplastic syndromes and related disorders (the ELASTIC study)
    Sternberg, Alexander
    Boucher, Rebecca
    Coulthard, Helen Chantal
    Raghavan, Manoj
    Culligan, Dominic
    Jackson, Aimee
    Cargo, Catherine
    Dennis, Mike
    Metzner, Marlen
    O'Sullivan, Jennifer
    Moore, Rachel
    Bowen, David
    Vyas, Paresh
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 222 - 229
  • [34] PI-PLCbeta1 expression in patients with high-risk Myelodysplastic syndromes is affected by azacitidine treatment.
    Finelli, Carlo
    Follo, Matilde Y.
    Bosi, Costanza
    Mongiorgi, Sara
    Clissa, Cristina
    Martinelli, Giovanni
    Baccarani, Michele
    Martelli, Alberto M.
    Cocco, Lucio
    BLOOD, 2007, 110 (11) : 722A - 722A
  • [35] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Cook, Rachel
    Jacoby, Meagan
    Nowak, Daniel
    Chyla, Brenda
    Zhou, Ying
    Ku, Grace
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [36] 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
    Breccia, Massimo
    Loglisci, Giuseppina
    Salaroli, Adriano
    Serrao, Alessandra
    Petrucci, Luigi
    Mancini, Marco
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1558 - 1560
  • [37] Treatment of high-risk myelodysplastic syndromes
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 12 - 13
  • [38] Management of high-risk myelodysplastic syndromes
    Pisani, FD
    Rainaldi, A
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (03) : 215 - 228
  • [39] Treating high-risk myelodysplastic syndromes
    Ades, Lionel
    BULLETIN DU CANCER, 2023, 110 (11) : 1162 - 1167
  • [40] Treatment of high-risk myelodysplastic syndromes
    Kroeger, Nicolaus
    HAEMATOLOGICA, 2025, 110 (02) : 339 - 349
12345